Johnson & Johnson’s nipocalimab meets primary endpoint in Sjögren’s disease trial
Johnson & Johnson (NYSE: JNJ), a global leader in healthcare, announced significant progress in the treatment of Sjögren's disease (SjD) with its drug, nipocalimab. In ... Read More
Innovent Biologics reports significant clinical success with picankibart in psoriasis treatment
Innovent Biologics, Inc. (HKEX: 01801) has announced remarkable results from the CLEAR-1 Phase 3 registrational study of its novel drug, picankibart (R & D code: ... Read More